Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
STUDY QUESTION: Do different dosages of metformin account for different clinical and biochemical outcomes in women with polycystic ovary syndrome (PCOS) and do basal anthropometric and metabolic characteristics of the patients provide any indications regarding the dose required to reach the target effect? SUMMARY ANSWER: Different doses of metformin exerted the same effects on clinical, biochemical and metabolic parameters in patients affected by PCOS. WHAT IS KNOWN AND WHAT THIS PAPER ADDS: Since the insulin-sensitizing agents came into use in the management of PCOS, metformin has shown a positive benefits-risks ratio. Nonetheless, therapeutic schedules are not well standardized. This is the first study which systematically analyses the effect of different doses of metformin on clinical, hormonal and metabolic features of PCOS. On the basis of our results, higher doses are no more effective than lower doses. DESIGN: A multicentric cohort prospective study. A total of 250 PCOS women were enrolled, 49 lost to follow-up. Menstrual cyclicity, hormonal assays, oral glucose tolerance test, lipid profile and ultrasonographic pelvic examination were evaluated at the baseline and after 6 months of metformin treatment at different doses (1000, 1500 and 1700 mg). PARTICIPANTS AND SETTING: A total of 201 PCOS patients completed the study without protocol violations in three university hospitals: seventy-three patients from Centre A (treated with metformin 500 mg twice a day), 60 patients from Centre B (treated with metformin 500 mg three times a day) and 68 patients from Centre C (treated with metformin 850 mg twice a day). MAIN RESULTS AND THE ROLE OF CHANCE: Metformin exerted an overall positive effect on the clinical and endocrine-metabolic features of PCOS. The degree of these effects was independent of the administered dosage in every range of basal body mass index (BMI). When patients were stratified according to their insulinaemic status, scattered inter-doses differences were found in some of the outcome measures. Patients who exhibited an increase of >2 menstrual cycles/year were considered as responders to treatment. Responders had a higher basal BMI than non-responders and showed a greater reduction in plasma testosterone levels after metformin treatment, but other outcome measures did not differ significantly. Total insulin secretion in the 180 min following the glucose tolerance test before metformin treatment (basal AUC-I) was significantly correlated with the decrease in insulin secretion induced by metformin in both the whole group and in responders, but only correlated with the variation in the number of cycles in responders. BIAS, CONFOUNDING AND OTHER REASONS FOR CAUTION: The different doses were administered in different centres, and between-centre variation is a potential confounding factor. GENERALIZABILITY TO OTHER POPULATIONS: The paradigm of using the minimum effective dose of metformin could be pursued in other pathological conditions characterized by insulin resistance. STUDY FUNDING/COMPETING INTEREST(S): No funding or competing interests to declare.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, metformin may induce mild to severe gastrointestinal side effects such as nausea, diarrhea, vomiting, and flatulence [11].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [11]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 3×
“The evaluation of insulin sensitivity was made by the homeostatic index (HOMA), which was calculated as follows: HOMA 1⁄4 [fasting insulin (mU/ ml) × fasting glucose (mmol/l)/22, 5] (Matthews et al., 1985).”
MethodInfluentialClassification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565 · cited 2×
“50% of PCOS women, is the most important determinant of insulin resistance and hyperinsulinaemia, which, nevertheless, also affects 30% of normal weight subjects (Ciampelli and Lanzone, 1998) The high circulating levels of insulin act at various levels of the hypothalamic–pituitary–ovarian axis, as well as on the hepa…”
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027 · cited 1×
“The most commonly reported side effects are nausea, vomiting and gastrointestinal distress, such as diarrhoea, flatulence and abdominal discomfort (Legro et al., 2007; Tang et al., 2012).”
BackgroundPrevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 1×
“Since the first report in 1994 (Velazquez et al., 1994), .500 original studies on metformin administration in PCOS have been published: most of them reported an improvement in insulin sensitivity, body mass index (BMI) and menstrual pattern, and a decrease in androgen levels (Moghetti et al., 2000).”
BackgroundNestler, J. E., Jakubowicz, D. J., Evans, W. S., & Pasquali, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382603 · Cited by 784 · cited 2×
“This finding is in line with some and in contrast to other studies in the literature: some authors, indeed, documented that metformin may restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely…”
BackgroundResultSelf-citationNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743 · cited 1×
“…and in contrast to other studies in the literature: some authors, indeed, documented that metformin may restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely associated…”
ResultTang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6293 · Cited by 660
Genotyping steroid 21-hydroxylase deficiency: hormonal reference data
NEW, M. I., LORENZEN, F., LERNER, A. J., KOHN, B., OBERFIELD, S. E., POLLACK, M. S., DUPONT, B., STONER, E., LEVY, D. J., PANG, S., et al. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-320 · Cited by 624 · cited 1×
“In all patients showing high levels of 17 hydroxyprogesterone (17OH-P), an adrenocorticotropic hormone test was performed (250 mm IV of Synacthen, Ciba-Geigy, Basel, Switzerland) to exclude the presence of late-onset adrenal enzyme defect, according to the criteria defined by New et al. (1983).”
MethodEfficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519 · cited 1×
“In patients with type 2 DM, the maximal benefits were achieved at the upper limits of the recommended daily dosage (Garber et al., 1997).”
BackgroundDunaif, A. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.3.942 · Cited by 450 · cited 1×
“This finding indirectly supports previous observations regarding the absence of a direct cause–effect relationship between insulinresistance and hyperinsulinaemia in PCOS women, that is peculiar to the syndrome itself (Dunaif and Finegood, 1996; Ciampelli et al., 1997).”
ResultPalomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Dunn, C. J., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549050-00007 · Cited by 391 · cited 2×
“The gastrointestinal absorption of the drug ranges from 20 to 30% and is dose dependent in humans, proportionally greater for a dose of 500 mg than for 1500 mg, as transport occurs almost exclusively via the paracellular route and is saturable (Dunn and Peters, 1995).”
BackgroundNestler, J. E., & Jakubowicz, D. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4431 · Cited by 368 · cited 1×
“…in the literature: some authors, indeed, documented that metformin may restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely associated with an ovulatory response to…”
BackgroundPolycystic ovary syndrome: Syndrome XX?
Sam, S., & Dunaif, A. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2003.08.002 · Cited by 302 · cited 1×
“Furthermore, the syndrome is burdened with long-term sequelae later in life: the PCOS population is at increased risk of cardiovascular disease (CVD), type 2 diabetes mellitus (DM) and metabolic syndrome (Sam and Dunaif, 2003; Apridonidze et al., 2005).”
BackgroundGenetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin
Song, I., Shin, H., Shim, E., Jung, I., Kim, W., Shon, J., & Shin, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.61 · Cited by 268 · cited 1×
“Furthermore, genetic polymorphism in the organic cation transporters of metformin were reported to be associated with changes in pharmacokinetics and pharmacodynamics (Song et al., 2008, Gambineri et al., 2010).”
BackgroundMetformin directly inhibits androgen production in human thecal cells
Attia, G. R., Rainey, W. E., & Carr, B. R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01975-6 · Cited by 256 · cited 1×
“Furthermore, metformin is supposed to restore ovulation through insulin-independent mechanisms, by reducing the expression of steroidogenic acute regulatory protein and, therefore, the thecal androgens production (Attia et al., 2001).”
BackgroundMetformin has direct effects on human ovarian steroidogenesis
Mansfield, R., Galea, R., Brincat, M., Hole, D., & Mason, H. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04925-7 · Cited by 237 · cited 1×
“Recently, (Mansfield et al. (2003) confirmed a decrease in androstenedione production by theca cells from pooled follicles incubated in the presence of metformin.”
BackgroundPCOS Forum: research in polycystic ovary syndrome today and tomorrow: Forum in PCOS research
Pasquali, R., Stener-Victorin, E., Yildiz, B. O., Duleba, A. J., Hoeger, K., Mason, H., Homburg, R., Hickey, T., Franks, S., Tapanainen, J. S., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03956.x · Cited by 185 · cited 4×
“In accordance with the Rotterdam Consensus Conference (Rotterdam ESHRE/ASRM 2004; Pasquali et al., 2011), PCOS was diagnosed in the presence of at least two of the following criteria: irregular menstrual cycles (or amenorrhea), clinical and/or biochemical evidence of hyperandrogenism and ultrasound…”
BackgroundMethodInfluentialSelf-citationMetformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of Doses
Harborne, L. R., Sattar, N., Norman, J. E., & Fleming, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2283 · Cited by 166 · cited 6×
“Partially in agreement with the aforementioned studies (Harborne et al., 2005; Bruno et al., 2007), the reduction in BMI was the only variable responding to metformin in a dose-related manner: after dividing the subjects on the basis of baseline BMI, we observed a tendency, devoid of statistical…”
BackgroundResultInfluentialGoodarzi, M. O., & Bryer‐Ash, M. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00448.x · Cited by 162 · cited 1×
“Indeed, several convincing evidence indicate that 1000 mg could be sufficient to reach treatment success both in DM type 2 patients and in PCOS women (Goodarzi and Bryer-Ash, 2005; Romualdi et al., 2008, 2010).”
BackgroundMaciel, G. A. R., Soares Júnior, J. M., Alves da Motta, E. L., Abi Haidar, M., de Lima, G. R., & Baracat, E. C. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.08.012 · Cited by 161 · cited 2×
“…restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely associated with an ovulatory response to the treatment (Maciel et al., 2004; Onalan et al., 2005; Legro et al., 2008).”
BackgroundFulghesu, A. M., Ciampelli, M., Belosi, C., Apa, R., Pavone, V., & Lanzone, A. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01919-7 · Cited by 151 · cited 1×
“…assessment of polycystic ovaries [bilateral normal or enlarged ovaries with at least 10 microcysts (2–8 mm diameter) from the inner margin to the outer margin in longitudinal cross section, associated with an augmented stromal area/total area ratio on ultrasonography; Fulghesu et al., 2001].”
BackgroundSelf-citationMetformin – the gold standard in type 2 diabetes: what does the evidence tell us?
Bosi, E. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01031.x · Cited by 134 · cited 1×
“Since the incidence of these adverse effects could reach up to 30% in PCOS women (Palomba et al., 2009), and the magnitude is dose related, the minimal effective dosage should be preferred in order to reduce the patient’s symptoms (Bosi, 2009).”
BackgroundNestler, J. E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4075 · Cited by 126
Ciampelli, M., Fulghesu, A. M., Cucinelli, F., Pavone, V., Caruso, A., Mancuso, S., & Lanzone, A. (1997) · Human Reproduction · doi:10.1093/humrep/12.9.1897 · Cited by 115
Self-citationLegro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1736 · Cited by 102 · cited 1×
“…restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely associated with an ovulatory response to the treatment (Maciel et al., 2004; Onalan et al., 2005; Legro et al., 2008).”
BackgroundÖnalan, G., Göktolga, Ü., Ceyhan, T., Bağış, T., Önalan, R., & Pabuçcu, R. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2005.05.010 · Cited by 71 · cited 2×
“…restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely associated with an ovulatory response to the treatment (Maciel et al., 2004; Onalan et al., 2005; Legro et al., 2008).”
BackgroundPalomba, S., Falbo, A., Russo, T., Orio, F., Tolino, A., & Zullo, F. (2010) · Human Reproduction · doi:10.1093/humrep/dep466 · Cited by 67 · cited 2×
“…and paracrine regulation of follicular growth and steroidogenesis could be advocated: different dosage of metformin may act with similar potency in increasing insulin-like growth factor (IGF) II, IGF-binding protein-1 and -3, which might improve local insulin sensitivity (Palomba et al., 2010).”
BackgroundRomualdi, D., Giuliani, M., Cristello, F., Fulghesu, A. M., Selvaggi, L., Lanzone, A., & Guido, M. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.01.114 · Cited by 58 · cited 1×
“Indeed, several convincing evidence indicate that 1000 mg could be sufficient to reach treatment success both in DM type 2 patients and in PCOS women (Goodarzi and Bryer-Ash, 2005; Romualdi et al., 2008, 2010).”
BackgroundSelf-citationGambineri, A., Tomassoni, F., Gasparini, D. I., Di Rocco, A., Mantovani, V., Pagotto, U., Altieri, P., Sanna, S., Fulghesu, A. M., & Pasquali, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0145 · Cited by 53 · cited 1×
“Furthermore, genetic polymorphism in the organic cation transporters of metformin were reported to be associated with changes in pharmacokinetics and pharmacodynamics (Song et al., 2008, Gambineri et al., 2010).”
BackgroundSelf-citationBruno, R. V., de Ávila, M. A. P., Neves, F. B., Nardi, A. E., Crespo, C. M. S., & Sobrinho, A. T. C. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.133 · Cited by 45 · cited 6×
“ifications, suggested that higher doses of metformin could be more effective compared with lower doses in overweight and obese PCOS women (Bruno et al., 2007).”
BackgroundResultInfluentialMetformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective
Romualdi, D., Costantini, B., Selvaggi, L., Giuliani, M., Cristello, F., Macrì, F., Bompiani, A., Lanzone, A., & Guido, M. (2008) · Human Reproduction · doi:10.1093/humrep/den230 · Cited by 45 · cited 1×
“Indeed, several convincing evidence indicate that 1000 mg could be sufficient to reach treatment success both in DM type 2 patients and in PCOS women (Goodarzi and Bryer-Ash, 2005; Romualdi et al., 2008, 2010).”
BackgroundSelf-citationInsulin and polycystic ovary syndrome: A new look at an old subject
Ciampelli, M., & Lanzone, A. (1998) · Gynecological Endocrinology · doi:10.3109/09513599809015601 · Cited by 42 · cited 2×
“…is the most important determinant of insulin resistance and hyperinsulinaemia, which, nevertheless, also affects 30% of normal weight subjects (Ciampelli and Lanzone, 1998) The high circulating levels of insulin act at various levels of the hypothalamic–pituitary–ovarian axis, as well as on…”
BackgroundSelf-citationLee, M. G., Choi, Y. H., & Lee, I. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j35p4x · Cited by 41 · cited 1×
“The degree of insulin-resistance itself may induce significant variations in the hepatic or renal clearance of metformin (Lee et al., 2008).”
BackgroundDietary Guidelines for Americans, 1990 edition
Peterkin, B. B. (1990) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(21)01887-3 · Cited by 36 · cited 1×
“Waist and hip circumference were measured as previously referred (Peterkin, 1990), and the WHR cut-off for a normal body fat distribution was settled at 0.80.”
MethodInfluentialWeerakiet, S., Sophonsritsuk, A., Lertvikool, S., Satirapot, C., Leelaphiwat, S., & Jultanmas, R. (2011) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2010.01507.x · Cited by 11 · cited 1×
“More recently, Weerakiet et al. (2011) reported similar pregnancy rates by adding 1000 or 1700 mg/day of metformin to clomiphene citrate in PCOS.”
Background
Research works printed but not linked: 1
- Moghetti, 2000, Journal of Clinical Endocrinology & Metabolism, 85, 139, 10.1210/jc.85.1.139 · doi:10.1210/jc.85.1.139 · Paper page
Cited by
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“However, metformin may induce mild to severe gastrointestinal side effects such as nausea, diarrhea, vomiting, and flatulence [11].”
BackgroundXing, C., Zhang, J., Zhao, H., & He, B. (2022) · International Journal of Women's Health · doi:10.2147/ijwh.s344542 · Cited by 118
“The observed poor compliance has prompted clinicians worldwide to find new ways to treat PCOS.(79) Table 1 Characteristics of the Included RCTs of Intervention on Changes of Serum SHBG”
BackgroundFavourable metabolic effects of a eucaloric lower‐carbohydrate diet in women with PCOS
Gower, B. A., Chandler‐Laney, P. C., Ovalle, F., Goree, L. L., Azziz, R., Desmond, R. A., Granger, W. M., Goss, A. M., & Bates, G. W. (2013) · Clinical Endocrinology · doi:10.1111/cen.12175 · Cited by 108
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94
“However, its use may be limited by significant side effects such as nausea, vomiting, and gastrointestinal discomfort [8].”
BackgroundMetformin: The hidden chronicles of a magic drug
Mahmood, K., Naeem, M., & Rahimnajjad, N. A. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.10.011 · Cited by 87
“Metformin affects the cardiometabolic parameters independent of the dosage administered [39].”
Background
Metadata
- Authors
- Fulghesu, A. M., Romualdi, D., Di Florio, C., Sanna, S., Tagliaferri, V., Gambineri, A., Tomassoni, F., Minerba, L., Pasquali, R., & Lanzone, A.
- Affiliations
- University of Cagliari (IT)
- Università Cattolica del Sacro Cuore (IT)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Corresponding author
- Romualdi, D.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-10
- Volume
- 27
- Issue
- 10
- Pages
- 3057-3066
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2155450883
- Cited by
- 48
- References
- 41
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 7 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- metformin, polycystic ovary syndrome, dose-response relationship, insulin sensitizers, menstrual cyclicity, insulin resistance, insulin secretion, testosterone, body mass index, oral glucose tolerance test, lipid profile, insulin-sensitizing therapy, predictors of treatment response, dose standardization
- MeSH terms
- Adult, Dose-Response Relationship, Drug, Female, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Menstrual Cycle, Metformin, Polycystic Ovary Syndrome, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.